Magnetic Resonance Imaging Markers for Cognitive Impairment in Parkinson’s Disease: Current View

Frontiers in Aging Neuroscience

Aging Neuroscience

Yanbing Hou¹  Huifang Shang² 

[1] Laboratory of Neurodegenerative Disorders, Department of Neurology, Rare Diseases Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China;null;

关键词: Parkinson’s disease;    magnetic resonance imaging;    biomarker;    mild cognitive impairment;    dementia;   

DOI  :  10.3389/fnagi.2022.788846

 received in 2021-10-03, accepted in 2022-01-03,  发布年份 2022

来源: Frontiers

【 摘 要 】

Cognitive impairment (CI) ranging from mild cognitive impairment (MCI) to dementia is a common and disturbing complication in patients with Parkinson’s disease (PD). Numerous studies have focused on neuropathological mechanisms underlying CI in PD, along with the identification of specific biomarkers for CI. Magnetic resonance imaging (MRI), a promising method, has been adopted to examine the changes in the brain and identify the candidate biomarkers associated with CI. In this review, we have summarized the potential biomarkers for CI in PD which have been identified through multi-modal MRI studies. Structural MRI technology is widely used in biomarker research. Specific patterns of gray matter atrophy are promising predictors of the evolution of CI in patients with PD. Moreover, other MRI techniques, such as MRI related to small-vessel disease, neuromelanin-sensitive MRI, quantitative susceptibility mapping, MR diffusion imaging, MRI related to cerebrovascular abnormality, resting-state functional MRI, and proton magnetic resonance spectroscopy, can provide imaging features with a good degree of prediction for CI. In the future, novel combined biomarkers should be developed using the recognized analysis tools and predictive algorithms in both cross-sectional and longitudinal studies.

【 授权许可】

Unknown   
Copyright © 2022 Hou and Shang.